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http://www.biomedcentral.com/1471-2415/14/107RESEARCH ARTICLE Open AccessUse of Mitomycin C to reduce the incidence of
encapsulated cysts following ahmed glaucoma
valve implantation in refractory glaucoma
patients: a new technique
Minwen Zhou2,3, Wei Wang1, Wenbin Huang1 and Xiulan Zhang1*Abstract
Background: To evaluate the surgical outcome of Ahmed glaucoma valve (AGV) implantation with a new
technique of mitomycin C (MMC) application.
Methods: This is a retrospective study. All patients with refractory glaucoma underwent FP-7 AGV implantation.
Two methods of MMC application were used. In the traditional technique, 6 × 4 mm cotton soaked with MMC
(0.25–0.33 mg/ml) was placed in the implantation area for 2–5mins; in the new technique, the valve plate first was
encompassed with a thin layer of cotton soaked with MMC, then inserted into the same area. A 200 ml balanced
salt solution was applied for irrigation of MMC. The surgical success rate, intraocular pressure (IOP), number of
anti-glaucoma medications used, and postoperative complications were analyzed between the groups.
Results: The surgical outcomes of two MMC applied techniques were compared. The new technique group had
only one case (2.6%) of encapsulated cyst formation out of 38 eyes, while there were eight (19.5%) cases out of 41
eyes the in traditional group. The difference was statistically significant (P = 0.030). According to the definition of
success rate, there was 89.5% in the new technique group and 70.7% in the traditional group at the follow-up end
point. There was a significant difference between the two groups (P = 0.035). Mean IOP in the new technique group
were significantly lower than those of the traditional group at 3 and 6 months (P < 0.05).
Conclusions: By using a thin layer of cotton soaked with MMC to encompass the valve plate, the new MMC
application technique could greatly decrease the incidence of encapsulated cyst and increase the success rate
following AGV implantation.
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Ahmed glaucoma valve (AGV) implantation has been
widely used and has been proved to be an effective
method for treating refractory glaucoma [1-4]. Several
studies in the literature have reported success rates of
AGV implantation ranging from 49% to 83.6% [1,3,5-7].
Encapsulated cyst formation is one of the main reasons
for failure [8]. The proliferation of fibrous tissue around
the implant plates blocks the diffusion of aqueous humor* Correspondence: zhangxl2@mail.sysu.edu.cn
1Zhongshan Ophthalmic Center, State Key Laboratory of Ophthalmology,
Sun Yat-Sen University, 54S.Xianlie Road, Guangzhou 510060, China
Full list of author information is available at the end of the article
© 2014 Zhou et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.and elevates intraocular pressure (IOP) [9]. Adjunctive use
of antimetabolites can greatly inhibit fibrosis [10,11], and
mitomycin C (MMC) has been used extensively in filter-
ing and glaucoma drainage device implant surgery [12,13].
However, how to use MMC more effective has remained
to be explored further. Heuer et al. [14]. Found that
double-plate Molteno implantation more frequently af-
fords IOP control than single-plate Molteno. Assuming
that the expanded surface area of the implant plate allows
reduced occurrence of encapsulated cyst, it is also sup-
posed that expanding the MMC function area in the
scleral bed where the AGV is placed may decrease encap-
sulated cyst formation. Unfortunately, the cotton soakedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 The different way of MMC application technique.
A: The traditional MMC application way: a piece of cotton soaked
MMC was inserted directly. B: The new technique way: a thin layer
of cotton soaked with MMC to encompass the valve plate, then
inserted the place of AGV placed.
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rolls into a mass, without a guarantee of enough size.
Therefore, we improved the method by introducing a
novel way for MMC to be used: the valve plate was first
encompassed with a thin layer of cotton soaked with
MMC, then insert into the implanted area. In this study,
we evaluated its surgical outcomes to see whether the new
method could produce better surgical results.
Methods
Patients and inclusion criteria
This was a retrospective study of patients diagnosed with
refractory glaucomas (including failed filtration, uveitic
glaucoma, pseudophakia, and traumatic glaucoma) who
underwent AGV implantation at the Glaucoma Depart-
ment of Zhongshan Ophthalmic Center. Consecutive pa-
tients followed up at the Zhongshan Ophthalmic Center
from October 2008 and January 2013 were included in
this study. From October 2008 to January 2010, we
employed the traditional method in our hospital, and we
converted to the new technique from January 2010. It
was approved by the Ethical Review Committee of
Zhongshan Ophthalmic Center and adhered to the pro-
visions of the Declaration of Helsinki for research in-
volving human subjects.
Best corrected visual acuity (BCVA), IOP, number of
antiglaucoma medications, and systemic diseases were
examined by chart review. Demographic data, such as
age, sex, prior surgery history, and subtypes of glaucoma
were collected. All patients received MMC application
during the surgery. Age less than 18 years, previous
aqueous shunt surgery in the same eye, prior scleral
buckling procedures, and without MMC application,
were all factors for excluding patients from the study.
Surgical techniques and MMC application
One glaucoma specialist (XZ) performed all the FP-7
AGV implantation surgeries, using the same techniques.
A fornix-based flap of the conjunctiva and Tenon cap-
sule was created in the superior temporal quadrant.
However, in the patients who had undergone previous
eye surgery, such as trabeculectomy, causing scarring of
the conjunctiva of the superior temporal quadrant, we
used an inferior temporal quadrant incision. The tube of
the AGV was flushed with a balanced salt solution
through a scleral track to ensure patency before inser-
tion. In order to decrease the possibility of overfiltering
following AGV implantation, the tube was ligated tightly
to restrict aqueous flow, using 8–0 polyglactin absorb-
able sutures, in all patients. The AGV was positioned in
the middle of the quadrant, with the anterior edge of the
plate 10 mm or more posterior to the superior temporal
corneoscleral limbus. Before the AGV was placed, MMC
(0.25–0.33 mg/ml, 2–5 min) was applied in all patients(Figure 1). The concentration and time of MMC
depended on the judgment of the risk of failure of the
surgery by the surgeon. In the traditional manner, a
piece of cotton (6 × 4 mm) soaked with MMC was
placed in the appointed area. However, the wet cotton
often rolled into a mass, without a guarantee of enough
size. In the improved manner, the valve plate was first
encompassed with a thin layer of cotton soaked with
MMC, then inserted into the same area. After 2–5 mi-
nutes, the cotton pieces and the encompassed AGVs
were removed and irrigated with 200 ml of balanced salt
solution. Then, the valve plate was sutured to the sclera
with 6–0 nylon sutures through the anterior positional
holes of the body of the valve plate. A half-thickness,
rectangular, 4 × 6 mm, limbal-based scleral flap was cre-
ated. The tip of the drainage tube was then cut and bev-
eled upwards, in order to extend it by 2 mm into the
anterior chamber. Paracentesis in the inferior temporal
peripheral cornea was performed, and viscoelastic was
injected to maintain the anterior chamber before tube
insertion. A 23-gauge needle punctured the anterior
chamber under the scleral flap, and the drainage tube
was inserted. The tube was sutured to the episcleral sur-
face with 8–0 polyglactin sutures. The scleral flap over
the drainage tube was reattached to the sclera and su-
tured with 10–0 nylon sutures. The conjunctiva and
Tenon capsule were reapproximated to the limbus with
8–0 polyglactin sutures. Topical prednisolone acetate 1%
(prednisolone acetate ophthalmic suspension, USP; PA)
was administered four times daily for four weeks, and
was then replaced with non-steroid anti-inflammatory
drug eye drops (pranoprofen 0.1% [Senju, Japan; PF]) for
two weeks. Glaucoma medications were prescribed when
the postoperative IOP was greater than 21 mm Hg, and
the medications were added or removed according to
the IOP level. Topical β-blockers were the first line of
therapy. Topical carbonic anhydrase inhibitor and top-
ical α2-adrenergic agonists were added as a second line
of therapy. Systemic medications to decrease IOP were
applied if necessary. When the IOP was reduced after
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drawn during the follow-up.
Postoperative follow-up
Postoperative IOP and VA were recorded at each visit
after AGV implantation surgery. The number of postop-
erative glaucoma medications and postoperative compli-
cations were recorded. The postoperative visits were
performed after 1 day, 1 week, 1 month, 3 months, and
every 6 months thereafter.
Evaluation criteria
Postoperative survival was defined as IOP <21 mm Hg,
with or without glaucoma medications, and without sig-
nificant visually threatening complications (endophthal-
mitis, retinal detachment, suprachoroidal hemorrhage,
preseptal cellulitis, or persistent hypotony [IOP < 5 mm
Hg]). Failure was defined as IOP not less than 21 mm
Hg, IOP < 5 mm Hg on two consecutive follow-up visits
after three months, or loss of light perception, or the
need for further surgery or laser to control IOP [15].
Statistical analysis
The data were processed and statistically analyzed using
SPSS for Windows XP (Version 13.0; SPSS, Chicago, IL).
The Mann–Whitney U test was used for variables with a
skewed distribution, and the chi-square or Fisher’s exact
test was used for categorical variables. An independentTable 1 Demographic and preoperative data of different grou
New techniqu
Age (y), mean ± SD 42.34 ± 1
Sex
Male, n (%) 23 (60.
Female, n (%) 15 (39.
Mean IOP (mm Hg), mean ± SD 41.97 ± 1
Mean glaucoma medication,mean ± SD 3.13 ± 0
Mean follow-up time (month), mean ± SD 19.89 ± 8
Mean best corrected visual acuity (logMAR) 1.82 ± 1
Mean MMC concentration (mg/ml) 0.29 ± 0
Mean MMC duration (min) 3.24 ± 0
Previous glaucoma surgeries history, n (%) 17 (44.
Diagnosis
Uveitic glaucoma, n (%) 10 (26.
NVG, n (%) 13 (34.
Traumatic glaucoma, n (%) 4 (10.5
ICE syndrome, n (%) 2 (5.3
Failed trabeculectomy, n (%) 9 (23.7
aindependent sample t test.
bchi-square test.
cMann–Whitney U test.
Abbreviations: SD indicates standard deviation, IOP introcular pressure, MMC mitomysample t test was used to compare normally distributed
continuous variables data between the two groups. To
compare the IOPs and glaucoma medications at various
time points before and after operation, the Wilcoxon
signed-rank test was used. Success rates in both groups
were compared using Kaplan–Meier survival curves and
the log rank test. P values of <0.05 were considered sta-
tistically significant.
Results
Seventy-nine eyes of 79 patients who fulfilled the inclu-
sion criteria were included in the study. MMC applied
with the traditional technique was performed in 41 eyes
(traditional group), while the new technique was per-
formed in the remaining 38 eyes (new technique group).
The minimum required follow-up period after surgery
was six months. Mean follow-up times were 19.89 ±
8.29 months for the new technique group and 18.10 ±
8.71 months for the traditional group (P = 0.938). The
demographic and preoperative data of the two groups
are presented in Table 1. There were no significant dif-
ferences in sex, mean age, mean IOP, mean BCVA, mean
glaucoma medication, or number of previous glaucoma
surgeries between the two groups.
Compared with preoperative IOP, the two groups
showed a statistically significant IOP decrease at all
follow-up intervals (P < 0.05, Wilcoxon signed-rank test).
IOP was lower in the traditional group than in the newp patients
e (n = 38) Traditional (n = 41) P




0.58 43.15 ± 9.63 0.608a
.58 3.24 ± 0.92 0.460c
.29 18.10 ± 8.71 0.938a
.25 2.24 ± 1.11 0.107c
.04 0.28 ± 0.04 0.155a
.97 3.00 ± 1.02 0.296a







cin C, NVG neovascular glaucoma, ICE Irido-corneal endothelial.
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Nevertheless, the new technique group showed lower
IOPs thereafter up to the end of the study in postopera-
tive month 30. The new technique group, compared
with traditional group, showed significantly lower IOP at
month 3 (P = 0.029) and month 6 (P = 0.043). Table 2
display the mean IOPs at all time intervals in both
groups.
Table 2 compares the mean numbers of antiglaucoma
medications required in both groups at all time intervals.
Medication use for both groups after surgery was signifi-
cantly decreased at all follow-up time points when co-
mpared with preoperative values (P < 0.05, Wilcoxon
signed-rank test). There were no statistically significantTable 2 Mean IOP and mean glaucoma medications required
Follow-up time New technique (n = 38, mm Hg
Preoperative
IOP (mmHg) 41.97 ± 10.58
Glaucoma medications 3.13 ± 0.58
Postoperative 1 day
IOP (mmHg) 20.03 ± 9.04
Glaucoma medications 0.21 ± 0.66
Postoperative 1 week
IOP (mmHg) 12.37 ± 5.05
Glaucoma medications 0.11 ± 0.51
Postoperative 1 month
IOP (mmHg) 13.45 ± 3.50
Glaucoma medications 0.03 ± 0.16
Postoperative 3 months
IOP (mmHg) 14.26 ± 4.96
Glaucoma medications 0.13 ± 0.53
Postoperative 6 months
IOP (mmHg) 14.71 ± 3.01
Glaucoma medications 0.34 ± 0.63
Postoperative 12 months
IOP (mmHg) 15.61 ± 5.20
Glaucoma medications 0.67 ± 1.03
Postoperative 18 months
IOP (mmHg) 16.23 ± 5.13
Glaucoma medications 0.85 ± 1.16
Postoperative 24 months
IOP (mmHg) 15.85 ± 1.96
Glaucoma medications 0.79 ± 0.97
Postoperative 30 months
IOP (mmHg) 15.75 ± 2.05
Glaucoma medications 0.63 ± 0.92
*Independent sample t-test or Mann–Whitney U test.
Abbreviations: IOP introcular pressure, SD standard deviation.differences between the groups at most of time point in
terms of the mean number of medications. However,
the new technique group had a significantly lower mean
number of medications than the traditional group at the
month 1 (P = 0.035) and month 3 (P = 0.025) postopera-
tive follow-up visit.
Kaplan–Meier survival analysis showed that the suc-
cess rates for the new technique and traditional groups
were 97.4% and 87.8% at 12 months, respectively, and
89.5% and 73.2% at 24 months, respectively. The success
rate of the new technique group was significantly higher
than that of the traditional group (P = 0.035, log rank
test) (Figure 2). After the endpoint of follow-up, failure
had occurred in 4 patients (10.5%) in the new techniquein both groups at all follow-up time intervals (mean ± SD)
) Traditional (n = 41, mm Hg) P*
43.15 ± 9.63 0.608
3.24 ± 0.92 0.460
16.15 ± 8.66 0.055
0.22 ± 0.00 0.683
11.46 ± 4.06 0.381
0.00 ± 0.00 0.505
15.15 ± 6.04 0.134
0.17 ± 0.38 0.035
17.34 ± 7.09 0.029
0.59 ± 1.09 0.025
17.27 ± 7.10 0.043
0.71 ± 1.17 0.442
16.90 ± 5.97 0.384
0.63 ± 1.16 0.590
16.38 ± 4.39 0.916
0.50 ± 1.00 0.310
17.33 ± 3.83 0.207
0.64 ± 1.15 0.667
16.20 ± 3.90 0.788
0.60 ± 1.34 0.833
Figure 2 Cumulative survival curves showed new technique
group had a greater survival than traditional group after AVG
implantation. There was significant difference between the 2
groups (P = 0.035).
Table 4 Mean best corrected visual acuity (logMAR) in
both groups at all follow-up time intervals (mean ± SD)
Follow-up time New technique
(n = 38, mm Hg)
Traditional
(n = 41, mm Hg)
P*
Preoperative 1.82 ± 1.25 2.24 ± 1.11 0.107
Postoperative 1 day 1.89 ± 1.22 2.30 ± 1.09 0.124
Postoperative 1 week 1.87 ± 1.21 2.18 ± 1.18 0.225
Postoperative 1 month 1.79 ± 1.25 2.12 ± 1.17 0.177
Postoperative 3 months 1.79 ± 1.25 2.10 ± 1.19 0.228
Postoperative 6 months 1.91 ± 1.35 2.09 ± 1.20 0.386
Postoperative 12 months 2.04 ± 1.21 2.11 ± 1.26 0.745
Postoperative 18 months 2.06 ± 1.24 2.02 ± 1.26 0.991
Postoperative 24 months 1.86 ± 0.91 2.28 ± 1.25 0.398
Postoperative 30 months 1.77 ± 0.92 2.62 ± 0.86 0.141
*Mann–Whitney U test.
Abbreviations: IOP introcular pressure, SD standard deviation.
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Table 3 showed the reasons for failure in both groups.
During the follow-up period, visual acuity remained
unchanged relative to pre-operative values. There were
no significant differences in visual acuity between the 2
groups at all time points (Table 4).
As shown in Table 5, postoperative complications in-
cluded encapsulated cyst formation, choroidal effusion, flat
anterior chamber, hypotony maculopathy, and hyphema.
The most common complication in the eyes of the trad-
itional group was encapsulated cyst formation, with inci-
dences in eight eyes (19.5%), while there was only an
incidence in one eye (2.6%) in the new technique group.
Statistically significant differences were detected between
the two groups when comparing encapsulated cyst forma-
tion complications (P = 0.030). Flat anterior chamber oc-
curred in five eyes (13.2%) in the new technique group.
There were no statistically significant differences in inci-
dences of other postoperative complications between the
groups.
Discussion
AGV implantation allows aqueous drainage via a tube
inserted into the anterior chamber to a posterior plate
sutured to the episclera. The aqueous humor crosses the





High IOP* (>21 mmHg) 2 (5.3%) 9 (22.0%)
Low IOP* (<5 mmHg) 1 (2.6%) 0
Progression to NLP 1 (2.6%) 1(2.4%)
Additional glaucoma surgery 0 1(2.4%)
*IOP-related failures require 2 consecutive visits at or after 3 months in which
the criterion is not met.removed from the periocular space by venous capillaries
or lymphatics [16,17]. However, when proliferation of fi-
brous tissue around the plate forms, it restricts aqueous
humor diffusion through the capsule, followed by a
gradual elevation of IOP, and then, encapsulated cyst
formation [8]. Encapsulated cyst formation is the most
frequent reason for glaucoma drainage device implant
surgery failure [8]. Adjunctive use of MMC is still con-
troversial; while most studies have concluded that ad-
junctive use of MMC is beneficial for improving success
rates [11,18,19], other studies have found that MMC did
not increase the short- or intermediate-term success
rates of AGV implantation [20,21]. Thus, further study
is expected to reveal whether adjunctive use of MMC is
beneficial, as well as how to use it more effectively in
AGV implantation.
In the process of AGV implantation, the traditional
method for placing MMC is to take a piece of cotton or
sponge soaked with MMC into the middle of the quad-
rant where the valve was to be implanted. In fact, the
cotton or sponge often folds or rolls into a mass at the
scleral bed, limiting the anti-fibrotic function of MMC.
In this study, the new technique, which overcame this
shortcoming, was able to guarantee enough fixed space






Encapsulated cyst formation, n (%) 1 (2.6%) 8 (19.5%) 0.030*
Choroidal effusion, n (%) 3 (7.9%) 1 (2.4%) 0.612
Flat anterior chamber, n (%) 5 (13.2%) 1 (2.4%) 0.072
Hypotony maculopathy, n (%) 1 (2.6%) 0 (0%) 0.481
Hyphema, n (%) 2 (5.3%) 4 (9.8%) 0.676
Fisher’s exact test.
*P < 0.05 between the two groups.
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significantly increase surgical outcomes.
This is the first study to compare the surgical outcome
and complication rates associated with the use of MMC
in AGV implantation, using the traditional and new
methods. Both methods showed efficacy and safety dur-
ing AGV implantation, and they showed a similar trend
in postoperative IOP control and the use of glaucoma
medication. Kaplan–Meier survival curves showed statis-
tically significant differences between the groups, which
might be a result of the lower incidences of encapsulated
cyst formation in the new technique group (one eye,
2.6% vs. eight eyes, 19.5% in the traditional group).
Comparing our findings with other reported series is
problematic, as some authors do not consider the forma-
tion of an encapsulated cyst as a complication and,
therefore, do not report it [22-24]. However, other stud-
ies have reported differences in incidences of encapsu-
lated cyst. Lai [25], in a series of 65 eyes undergoing
AGV implantation, reported that 16 eyes (24.6%) devel-
oped encapsulated cyst as a postoperative complication.
Similarly, a prospective, comparative study showed that
five eyes (14.7%) had incidences of encapsulated cyst
after AGV implantation [6]. In short, encapsulated cyst
formation is often referred to as a late complication after
glaucoma implant insertion in adults, with an appear-
ance varying from 5% to 30%, depending on study de-
sign, follow-up time, and patient selection. In our study,
encapsulated cyst occurred in only 2.6% of the new tech-
nique group. Therefore, by using a thin layer of cotton
soaked with MMC to encompass the valve plate, this
novel MMC application technique could greatly de-
crease the incidence of encapsulated cyst.
On the other hand, the incidence of flat anterior
chamber using the new technique method was higher
than using the traditional method. In fact, to avoid post-
operative hypotony, the tube was ligatured tightly, using
8–0 polyglactin suture, to restrict aqueous flow during
the surgery. Therefore, the use of adjunctive MMC may
be another cause of hypotony, besides leakage around
the tube, a decrease in aqueous production, and overfil-
tration [26]. Whether the new technique method of
MMC application allows more range for MMC func-
tioning to cause more flat chamber incidence needs to
be investigated further.
The main limitation of this study is the nonrandomized
design. We took every possible step to reduce potential
bias, and the final data were subjected to careful statistical
analysis. The crucial criterion for any “randomization” is
to have groups at the baseline comparable in demographic
and clinical characteristics. In this study, that was the case.
The second limitation is that different MMC concentra-
tions and times in different patient might affect result of
study.Conclusions
In conclusion, this study indicates that the new technique
for MMC application may provide a better chance for pa-
tients to decrease the incidence of encapsulated cyst, when
compared with the traditional method. In addition, there
was a tendency for lower IOP and higher complete suc-
cess rate in the new technique group.
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